Lipid peroxidation product acrolein as a predictive biomarker of prostate carcinoma relapse after radical surgery.
Cancer recurrence after radical surgery might happen even in the case of patients with localized prostate carcinoma treated by radical prostatectomy. Therefore, identifying predictive markers of tumour recurrence is very important, so this study evaluated the presence of lipid peroxidation product acrolein in primary prostate carcinomas, assuming that acrolein could be involved in prostate carcinogenesis as was recently shown for colon cancer. Samples obtained by radical prostatectomy of 70 patients were analysed, out of which 27 patients suffered afterwards from tumour recurrence, while 43 patients were disease free. Immunohistochemistry using genuine monoclonal antibodies against acrolein-protein adducts revealed the association of acrolein with progression of carcinoma. The logistic regression combining clinical parameters together with the biochemical markers of disease and acrolein immunohistochemistry has shown that the relapse might be predicted with 90% accuracy if tumour-positive surgical margins, stage of disease and the intensity of acrolein presence in tumour stroma were taken together.
Custovic
Zajim
Z
Department of Urology, General Hospital Dubrovnik, Croatia.
Zarkovic
Kamelija
K
Cindric
Marina
M
Cipak
Ana
A
Jurkovic
Ilija
I
Sonicki
Zdenko
Z
Uchida
Koji
K
Zarkovic
Neven
N
D000171:Acrolein / Q000378:metabolism*; D000368:Aged; D014408:Biomarkers, Tumor / Q000378:metabolism*; D006801:Humans; D007150:Immunohistochemistry; D015227:Lipid Peroxidation; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D011237:Predictive Value of Tests; D011471:Prostatic Neoplasms / Q000175:diagnosis / Q000378:metabolism* / Q000601:surgery*; D012008:Recurrence
D014408:Biomarkers, Tumor; D000171:Acrolein